Tirzepatide therapy counters inflammatory and apoptotic responses induced by high-fat diet in rat liver.
Wiad Lek · 2025
Last updated 2026-05-28In a study of 28 rats, those given tirzepatide (10 nmol/kg) for four weeks after eight weeks on a high-fat diet showed significant reductions in body weight, blood sugar, insulin, liver enzymes, and harmful fats like triglycerides. The treated rats also had lower levels of inflammatory markers (TNF-α, IL-1β) and a protein linked to cell death (caspase-3) in their liver tissue compared to untreated obese rats.
AI summary of the abstract below.
| Journal | Wiad Lek, 2025 |
|---|---|
| Citations | 2 |
| Molecules | tirzepatide |
| Conditions studied | Type 2 Diabetes, Obesity, Mash |
Abstract
OBJECTIVE: Aim: To examine potential protective effect of Tirzepatide against obesity-induced metabolic dysfunction and hepatic inflammatory and apoptotic responses.
PATIENTS AND METHODS: Materials and Methods: A total of 28 adult male Sprague-Dawley rats were employed and divided into four groups, normal control group involved seven rats fed a regular diet, while other rats received a high fat diet. Obese rats were separated into three groups after eight weeks of high fat diet: obesity, Tirzepatide (10 nmol/kg) s.c and vehicle groups, and treated for four weeks. Data regarding body weight, blood glucose, serum insulin, liver enzymes, and TNF-α, IL-1β and caspase-3 levels in the liver tissue were obtained.
RESULTS: Results: results revealed that Tirzepatide-treated obese rats exhibited significantly reduced body weight, blood glucose, serum insulin ALT, triglyceride, VLDL levels. Additionally, liver specimens from Tirzepatide group demonstrated lower levels of TNF-α, IL-1β and caspase-3 compared to obese untreated rats.
CONCLUSION: Conclusions: It concluded that Tirzepatide treatment mitigates the metabolic dysregulations induced by High Fat Diet, additionally; it ameliorates the inflammatory and apoptotic responses in hepatic tissue triggered by High Fat Diet.
Verbatim abstract via PubMed 40367464 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.